Sandoz digital “Scientific Standalone” event will help drive access to medical information in field of cardiovascular therapies

  • Sandoz Scientific Standalone event — “Reach Targets, Save Lives” – aims at increasing access to information in the field of cardiovascular therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
  • Lectures by leading cardiologists and internal medicine specialists will be recorded and offered for re-use across the region following the live event
  • Enhanced digital training can help improve health outcomes for patients

 

Holzkirchen, March 20, 2017 – …

/by

Sandoz digital “Scientific Standalone” event will help drive access to medical information in field of cardiovascular therapies

  • Sandoz Scientific Standalone event — “Reach Targets, Save Lives” – aims at increasing access to information in the field of cardiovascular therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
  • Lectures by leading cardiologists and internal medicine specialists will be recorded and offered for re-use across the region following the live event
  • Enhanced digital training can help improve health outcomes for patients

 

Holzkirchen, March 20, 2017 – …

/by

Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)

  • Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines.
  • Winning ideas proposed novel ways to use mobile technologies to connect patients with caregivers and essential medicines
  • Sandoz invited young people worldwide to “reimagine access to healthcare” – arguably the largest unmet medical need

London, March 13, 2017 – Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare …

/by

New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine

  • Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*
  • Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis
  • Study reinforces strength of Sandoz pipeline and its key role in the broader Novartis immunology portfolio

Holzkirchen, 6 March 2017 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today …

/by

Sandoz certified as Top Employer Europe 2017

  • Sandoz has been officially certified  by the Top Employers Institute for its exceptional employee offerings in Europe
  • The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world
  • This exclusive certification underlines our determination to attract and retain the best people from inside and outside our industry.”

Holzkirchen, February 8, 2017 – Sandoz, a Novartis division, is proud to announce that it has been officially certified  by the Top Employers …

/by

Sandoz confirms strategic commitment to drive access to medicines in Japan, with plan to double business by 2022

  • Japanese generic market set to expand rapidly, driven by government commitment to achieving sustainable high-quality healthcare
  • Sandoz Japan plans 70 new launches over next six years, which will account
    for ~40% of total sales by 2022
  • Growth drivers will include oncology, CNS and biosimilars

Tokyo, February 8, 2017 – Sandoz plans to double sales in Japan over the 2015 to 2022 period, as part of its long-term strategic plan to help drive access to hiqh-quality medicines in the Japanese market …

/by

Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback

  • FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance
    • Cosentyx (USD 1.1 billion) reached blockbuster status
    • Entresto (USD 170 million) continued to grow steadily, following positive treatment guidelines in US and Europe and ongoing US field force expansion
    • Gilenya (USD 3.1 billion, +14% cc) delivered double-digit growth
    • Oncology grew 12% (cc) excluding Gleevec/Glivec, driven by new assets and Jakavi
    • Sandoz Biopharmaceuticals[1] grew 31% (cc) to reach USD 1.0 billion …
/by

New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

  • ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1]
  • Interim data in over 600 adults show potential of GP2013 as an alternative rituximab[1]
  • Sandoz proposed biosimilar rituximab is the company’s first monoclonal antibody candidate

Holzkirchen, December 5, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial. The confirmatory safety and efficacy …

/by

Sandoz to donate up to USD 10 million of high-quality generic medicines annually to Americares to increase access to medicines

Princeton, New Jersey, November 22, 2016. Sandoz today announced a collaboration to increase access to medicines by donating up to USD 10 million of stock annually to Americares, a health-focused relief and development organization that responds to people affected by poverty or disaster with life-changing health programs, medicine and medical supplies.

The initial donation will include over 25 Sandoz products for treatment for infections, cardiovascular conditions, eyecare, skin conditions and musculoskeletal pain. It is part of the global Sandoz commitment to …

/by

Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator

  • No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1]
  • Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact on safety and efficacy[1]
  • Sandoz biosimilar etanercept was approved by the FDA* in August 2016 and is currently under review by the EMA**

Holzkirchen, November 18, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today …

/by